Clinical characteristics and drug–drug interactions in human epidermal growth factor receptor 2-positive breast cancer treated with trastuzumab deruxtecan: real-world data from the DE-REAL study
The Oncologist · 17.01.2026 · 31 (2)
DOI: 10.1093/oncolo/oyaf402 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Oncologist, online erschienen am 23.01.2026. Verfasst von Simona Pisegna und 24 weiteren Autor:innen. Beteiligte Einrichtung: Department of Experimental Medicine, Sapienza University of Rome, Rome, 00161, Italy. Hauptthemen laut MEDLINE: Breast Neoplasms, Erb-b2 Receptor Tyrosine Kinases, Trastuzumab, Immunoconjugates. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Trastuzumab deruxtecan (T-DXd) reshaped clinical practice in human epidermal growth factor receptor 2-positive (HER2+) metastatic breast cancer (mBC). The impact of clinical characteristics and drug–drug interactions (DDIs) on outcomes in patients receiving T-DXd is still under investigation.
Methods
We retrospectively analyzed data of patients from the Italian DE-REAL study. Clinical features including age, body mass index (BMI), toxicity and DDIs were assessed and correlated with clinical outcomes. The Drug-PIN software was used to evaluate DDIs.
Results
Among 143 patients, age did not significantly affect progression-free survival (PFS) but influenced overall survival (OS), with younger patients (<65 years) showing better outcomes (median overall survival [mOS]: 12 vs. 10 months, P = 0.02). Patients with BMI >25 demonstrated significantly longer PFS (11 vs. 9 months, P = 0.04), which was confirmed as independent predictor of better PFS at multivariate analysis (P ≤0.05), but experienced higher toxicity rates, particularly nausea (P = 0.019). Drug-PIN classification showed no impact on survival outcomes, although patients with high-risk DDIs experienced more nausea and asthenia compared to those with low-risk interactions (P = 0.0018 and P = 0.003, respectively).
Conclusion
T-DXd efficacy appears consistent across different age groups, although elderly patients showed reduced OS. Higher BMI was associated with improved PFS but increased toxicity. While DDIs did not affect survival outcomes, they influenced specific adverse events. Our results reinforce the efficacy and favorable safety profile of T-DXd in a broad real-world population, including patients with polypharmacy or comorbidities, while highlighting that personalized monitoring and supportive care strategies may be particularly beneficial for elderly patients and those with higher BMI.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Experimental Medicine, Sapienza University of Rome, Rome, 00161, Italy.
- Department of Radiological, Oncological and Pathological Science, Sapienza University of Rome, Rome, 00161, Italy.
- Department of Breast and Thoracic Oncology, Division of Breast Medical Oncology, Istituto Nazionale Tumori IRCCS "Fondazione Pascale, Naples, 80131, Italy.
- European Institute of Oncology, IRCCS, Milan, 20141, Italy.
- Department of Oncology and Hemato-Oncology, University of Milan, Milan, 20122, Italy.
- Department of Internal Medicine and Medical Specialties (DiMI), School of Medicine, University of Genova, Genoa, 16132, Italy.
ORCID-Profile: Simona Pisegna, Simone Scagnoli, Roberta Caputo, Michelino De Laurentiis, Giuseppe Curigliano, Matteo Lambertini, Armando Orlandi, Antonella Palazzo, Ida Paris, Alessandra Fabi, Andrea Botticelli
Zitieren
APA
Pisegna, S., Scagnoli, S., Gentile, G., Chiavassa, A., Caputo, R., De Laurentiis, M., Curigliano, G., Lambertini, M., Pantano, F., Orlandi, A., Palazzo, A., Paris, I., Vernieri, C., Tedesco, B., Giampaglia, M., Palleschi, M., Ballatore, Z., Alesini, D., D'Auria, G., …, & Botticelli, A. (2026). Clinical characteristics and drug–drug interactions in human epidermal growth factor receptor 2-positive breast cancer treated with trastuzumab deruxtecan: real-world data from the DE-REAL study. The Oncologist, 31(2). https://doi.org/10.1093/oncolo/oyaf402
Vancouver
Pisegna S, Scagnoli S, Gentile G, Chiavassa A, Caputo R, De Laurentiis M, et al. Clinical characteristics and drug–drug interactions in human epidermal growth factor receptor 2-positive breast cancer treated with trastuzumab deruxtecan: real-world data from the DE-REAL study. The Oncologist. 2026;31(2). doi:10.1093/oncolo/oyaf402
BibTeX
@article{Pisegna2026,
author = {Pisegna, Simona and Scagnoli, Simone and Gentile, Gabriella and Chiavassa, Antonella and Caputo, Roberta and De Laurentiis, Michelino and Curigliano, Giuseppe and Lambertini, Matteo and Pantano, Francesco and Orlandi, Armando and Palazzo, Antonella and Paris, Ida and Vernieri, Claudio and Tedesco, Beatrice and Giampaglia, Marianna and Palleschi, Michela and Ballatore, Zelmira and Alesini, Daniele and D'Auria, Giuliana and Fabbri, Maria Agnese and Rossi, Luigi and Fiscon, Giulia and Marchetti, Paolo and Fabi, Alessandra and Botticelli, Andrea},
title = {Clinical characteristics and drug–drug interactions in human epidermal growth factor receptor 2-positive breast cancer treated with trastuzumab deruxtecan: real-world data from the DE-REAL study},
journal = {The Oncologist},
year = {2026},
volume = {31},
number = {2},
doi = {10.1093/oncolo/oyaf402}
}
EUVIMED